Avingtrans Plc (LON:AVG) has delivered a first half where margins, EBITDA and earnings per share all moved decisively higher, while net debt remained stable despite continued investment in medical imaging. Beneath flat year-on-year revenue lies a shift in mix, stronger aftermarket performance and early positioning in AI-driven data centre cooling and new nuclear. With US regulatory approval secured for Adaptix and nuclear contracts building into the second half, the runway for growth is becoming increasingly visible.
Key Moments
- 00:30 – Financial performance overview
Margins, EBITDA and EPS all increased; net debt stable despite medical investment - 01:13 – Revenue explanation
Flat year-on-year revenue reflects an unusually strong H1 last year, with normal 45–55 H2 weighting expected - 02:19 – Margin drivers
Aftermarket strength in Engineering and AES divisions lifted profitability - 03:27 – AI data centres and new nuclear
TerraPower contract progression and rising nuclear demand driven by AI-related energy needs - 04:18 – Data centre cooling opportunity
Ormandy benefiting from backup cooling system demand across UK and Europe - 05:50 – Adaptix FDA approval
US 510(k) clearance achieved; distributors appointed; commercial ramp underway - 07:35 – Outlook
Stronger H2 expected; nuclear and medical imaging positioned as multi-year growth drivers; IPO and exits remain strategic options
About Avingtrans
Avingtrans Plc is a UK-based engineering group supplying critical components, systems and services to energy, nuclear, aerospace and medical imaging markets, with growing exposure to new nuclear and advanced imaging technologies.
